Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 11, 2004

                            BSD MEDICAL CORPORATION
             (Exact name of registrant as specified in its charter)

         Delaware                       0-10783                 75-1590407
(State or other jurisdiction          (Commission            (I.R.S. Employer
     of incorporation)                File Number)          Identification No.)

           2188 West 2200 South
       Salt Lake City, Utah                                            84119
(Address of principal executive offices)                             (Zip Code)

        Registrant's telephone number, including area code (801) 972-5555

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13a-4(c))

Item 7.01. Regulation FD Disclosure.

BSD Medical Corporation issued a press release on November 11, 2004. A copy of
the press release is hereby furnished as Exhibit 99.1 attached hereto Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

Item 9.01. Financial Statements and Exhibits.

(c)   Exhibits

99.1  Press Release of BSD Medical Corporation dated November 11, 2004

For Your Review and Approval
        BSD Medical Signs Best Medical International as U.S. Sales Agent

      SALT LAKE CITY,  November 11, 2004--BSD Medical Corp.  (OTCBB:BSDM)  today
announced that it has entered into an agreement with Best Medical International,
Inc. to act as BSD's  sales agent for sales of its BSD-500  system in the United
States.  Best  Medical is a leading  supplier of products  for cancer  treatment
therapies using targeted radiation sources (brachytherapy).

      Hyrum A. Mead,  president of BSD Medical said,  "For 27 years Best Medical
has been a foremost supplier of products used in the market segment targeted for
the  BSD-500.   The  BSD-500  is  used  in  combination  with  brachytherapy  to
substantially improve both tumor destruction and long-term survival from cancer,
as  compared  to  brachytherapy  treatments  alone.  We  expect  Best  Medical's
reputation for excellent  customer  service,  high quality products and customer
satisfaction, as provided by its strong sales force, to contribute greatly as we
partner in our sales efforts for the BSD-500."

      Krish Suthanthiran, President of Best Medical International said, "BSD and
Best Medical share a common market.  Best has frequent  communications  with the
physicians  and clinics that should be utilizing  BSD  technology.  We intend to
leverage the disposable business to sell the capital equipment and vice-versa."

      Two new FDA  approvals  were  granted  within  the past 13 months  for the
BSD-500.  These  approvals  culminated six years of planning and development for
the new system.  The BSD-500 is compact,  portable and ergonomically  engineered
for ease and convenient use in a demanding  hospital  environment.  The ultimate
sales  objective for the BSD-500 is to achieve 1:1  utilization  in  combination
with the 1,500  brachytherapy  systems  currently  installed--a  total potential
market of over $300 million.

      BSD Medical  Corporation is a leading  developer of microwave systems used
in the treatment of cancer.  For more  information  about BSD Medical Corp., its
products and therapies visit  www.BSDMC.com.  For further information about Best
Medical International, Inc. visit www.Best-Medical.com.

      Statements  contained in this press release that are not historical  facts
are  forward  looking  statements,  as  that  item  is  defined  in the  Private
Securities  Litigation  Reform  Act of  1995.  All  forward-looking  statements,
including  statements about the projected market for the BSD-500, are subject to
risks and  uncertainties,  some of which are  detailed in part in the  Company's
filings with the Securities and Exchange Commission.



      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: November 11, 2004

                                             By: /s/  Hyrum A. Mead